Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Delcath Systems Inc
DCTH | US
9.08
USD0
0%
DCTH | US
About Delcath Systems Inc
Sector
Healthcare
Industry
Diagnostics & Research
Earnings date
30/06/2024
As of date
06/03/2026
Close
9.08
Open
8.90
High
9.12
Low
8.90
Delcath Systems Inc. an interventional oncology company focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems Inc. was incorporated in 1988 and is headquartered in New York New York.
View LessDCTH | US
Risk
70.8
Sharpe
-0.63
Luna's Score
46/100
Recommendation
Hold
Luna says (DCTH | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
What's not Working
Price Below SMA10D
High Short-term Volatility
Microcap (<300M USD)
High Debt to Equity (> 0.75)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
76.0%1 month
70.8%3 months
49.3%6 months
52.0%Returns
Fundamental Ratios
PE
-
Fwd. PE
120.48
Price to book
68.33
Debt to equity
1.33
Debt to assets
0.16
Ent. to EBITDA
-1.92
Ent. to rev.
22.91
PEG
-
Other Fundamentals
EBITDA
-35.92M
MarketCap
254.25M
MarketCap(USD)
254.25M
Div. yield
-
Op. margin
-50.37
Erngs. growth
-
Rev. growth
1.47K
Ret. on equity
-478.59
Short ratio
4.62
Short perc.
4.34
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
1.74
Range1M
1.81
Range3M
2.67
Volumes: Market Activity
Rel. volume
0.65
Price X volume
3.26M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.92 | - | Cheaper |
| Ent. to Revenue | 22.91 | - | Cheaper |
| PE Ratio | - | 40.09 | - |
| Price to Book | 68.33 | 77.50 | Par |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 49.26 | - | Par |
| Debt to Equity | 1.33 | -14.36 | Expensive |
| Debt to Assets | 0.16 | 0.34 | Cheaper |
| Market Cap | 254.25M | - | Emerging |
